SOURCE: Bio-Rad Laboratories
HERCULES, CA--(Marketwired - Dec 10, 2013) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that Robert M. Malchione has been appointed to its Board of Directors effective January 1, 2014. Mr. Malchione will stand for election to the Board along with Bio-Rad's other directors at the Company's Annual Meeting on April 22, 2014.
Mr. Malchione has a broad range of experience in corporate strategy and technology development, most notably at Avery Dennison Corporation, where he served as Senior Vice President, Corporate Strategy and Technology from 2000 to 2011. Prior to that, he served as Vice President, Director and Partner at Boston Consulting Group.
Currently, Mr. Malchione is on the Board of Directors and Executive Committee for Innovate Pasadena. He is also an advisor to a start-up company developing system engineering tools for manufacturing companies.
Mr. Malchione holds a Master of Business Administration degree from Harvard Graduate School of Business Administration and a Bachelor of Science degree in mechanical engineering from Lehigh University.
"We are pleased to have Robert join our Board," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "His many years of experience working with large, global operations in a variety of areas will be a valuable addition to Bio-Rad."
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has been at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs approximately 7,600 people worldwide and had revenues exceeding $2 billion in 2012. Visit us at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.